Find public news by keyword, exact ticker, category and date.
Open a ticker page for its news coverage. The news search below stays a text search.
4 results loaded, newest first. End of these results.
Scynexis Inc announced Phase 1 study results for its experimental drug SCY-770, an oral direct AMPK activator for autosomal dominant polycystic kidney disease. The company stated SCY-770 was well tolerated with a favorable safety profile at higher doses. A Phase 2 study is on track to start in Q4 2026.
SCYNEXIS reported completed Phase 1 results for SCY-770, an oral AMPK activator in development for ADPKD. Results showed the drug was well tolerated with a favorable safety profile in healthy adults.
SCYNEXIS announced that SCY-770 was well tolerated in a Phase 1 study in healthy adults, supporting dose selection. A Phase 2 proof-of-concept trial in ADPKD is on track to initiate in Q4 2026.
SCYNEXIS announced Phase 1 study results for SCY-770, a novel, highly selective, oral direct AMPK activator for Autosomal Dominant Polycystic Kidney Disease (ADPKD). The drug candidate was well tolerated with a favorable safety profile in healthy adult participants at higher doses than previously evaluated. A Phase 2 p